Status:
RECRUITING
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Conditions:
Lung Cancer
Gastrointestinal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determ...
Eligibility Criteria
Inclusion
- Adults (age \>18 years) with a diagnosis of a head and neck, lung, gastrointestinal cancer, that are receiving concurrent chemotherapy and radiation treatment.
- Possession of a mobile device that can receive SMS texts and can deliver FitBit data wirelessly
- Ability read and respond in English
- Ability to provide informed consent to participate in the study
Exclusion
- Patients who are bed bound at baseline (ECOG 4)
- Patients who rely on a wheelchair for ambulation
Key Trial Info
Start Date :
May 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05318027
Start Date
May 22 2023
End Date
December 1 2025
Last Update
August 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104